Clinical Trials Browser

Phase 3 × pamiparib × 90 days × Clear all

NCT03519230 2026-03-16

Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer

Phase 3 Active not recruiting

Ovarian Neoplasms

NCT04164199 2026-03-16

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

Phase 3 Enrolling by invitation

Advanced Malignancies